Methyl and Acetyl-CoA Donor Composition for Mitochondrial Dysfunction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments do not effectively address mitochondrial dysfunction in diseases such as Xeroderma pigmentosum and other DNA repair deficiency syndromes, leading to increased sensitivity to UV radiation, skin cancer, and premature aging, as well as neuro-logical phenotypes and metabolic disorders.
Innovation Solution
A composition comprising a methyl-group donor and an acetyl-CoA donor, such as choline and acetate, is administered to increase ATP and acetyl-CoA production, stabilizing energy metabolism and protein levels, thereby alleviating mitochondrial dysfunction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for mitochondrial dysfunction in Xeroderma pigmentosum, then DNA repair deficiency can be addressed, but mitochondrial function remains impaired leading to increased UV sensitivity, skin cancer risk, and premature aging
Solution Approach 1:
The patent applies parameter changes by supplying alternative substrates (acetyl-CoA and methyl-group donors) to bypass the defective mitochondrial enzymes in XPA-deficient cells. This changes the metabolic parameters to compensate for the enzymatic deficiency, restoring ATP production and reducing UV sensitivity without requiring functional XPA protein.
Solution Approach 2:
The patent uses acetyl-CoA and methyl-group donor compounds as intermediary substances that mediate between the external environment and the defective mitochondrial system. These intermediaries provide the necessary metabolic substrates to compensate for the missing XPA enzyme function, thereby protecting against UV damage and reducing cancer risk.
2Power
If XPA-deficient cells are treated with standard therapies, then DNA repair deficiency is managed, but ATP production remains insufficient leading to cellular energy depletion and apoptosis
Solution Approach 1:
The patent changes the metabolic parameters by providing exogenous acetyl-CoA and methyl-group donors that can be processed through alternative pathways to generate ATP. This bypasses the defective mitochondrial enzymes and restores energy production capacity, preventing cellular energy depletion and apoptosis.
Solution Approach 2:
The patent ensures continuous ATP production by supplying alternative metabolic substrates that can be continuously processed through glycolysis and other energy-generating pathways. This maintains continuous cellular energy supply despite the mitochondrial enzyme deficiency, preventing energy depletion and cell death.
3Adaptability or versatility
If mitochondrial dysfunction is present in Xeroderma pigmentosum, then DNA repair is compromised, but additional signs of premature aging and neurological phenotypes develop due to metabolic dysfunction
Solution Approach 1:
The patent applies parameter changes by supplying alternative metabolic substrates (acetyl-CoA and methyl-group donors) that can be processed through multiple pathways to generate energy and protective molecules. This restores metabolic versatility and function, preventing the progression of premature aging and neurological phenotypes associated with mitochondrial dysfunction.
Solution Approach 2:
The patent uses compounds that serve multiple functions: acetyl-CoA provides energy through the citric acid cycle, serves as a substrate for acetylation reactions, and can be converted to ketone bodies. The methyl-group donors provide methyl groups for DNA methylation and also serve as energy substrates. This multi-functionality addresses both the DNA repair deficiency and the metabolic dysfunction simultaneously.
Data Source
AI summary
The present invention relates to compositions comprising a methyl group donor compound and an acetyl-CoA donor compound for use in therapy and prevention of diseases associated with dysfunction of mitochondriae, wherein the diseases associated with dysfunction of mitochondriae are nucleotide excision repair deficiency syndromes, especially Xeroderma pigmentosum A, or DNA repair deficiency syndrome ataxia telangiectasia associated with mitochondrial dysfunction. Particularly, the composition is used for therapy of nucleotide excision repair deficiency syndromes, such as Xeroderma pigmentosum A, B, C, D, E, F, G, V, the different forms of Cockayne syndrome (CS), such as Cockayne syndrome type B (CSB) and Cockayne syndrome type A (CSA), and trichothiodystrophy (TTD), or DNA repair deficiency syndrome ataxia telangiectasia associated with mitochondrial dysfunction.